These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 621716

  • 21. Comparison of current alkylating agents with a homo-aza-steroidal ester for antineoplastic activity.
    Catsoulacos P, Papageorgiou A, Margarity E, Mourelatos D, Mioglou E.
    Oncology; 1994; 51(1):74-8. PubMed ID: 8265107
    [Abstract] [Full Text] [Related]

  • 22. Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
    Misiura K, Kinas RW, Kuśnierczyk H.
    Bioorg Med Chem Lett; 2002 Feb 11; 12(3):427-31. PubMed ID: 11814813
    [Abstract] [Full Text] [Related]

  • 23. Synthesis and antitumor activity of two ifosfamide analogs with a five-membered ring.
    Kutscher B, Niemeyer U, Engel J, Kleemann A, Hilgard P, Pohl J, Scheffler G.
    Arzneimittelforschung; 1995 Mar 11; 45(3):323-6. PubMed ID: 7741794
    [Abstract] [Full Text] [Related]

  • 24. Some novel potential alkylating agents derived from diethylstilbestrol.
    Roushdi IM, Omar AM, Ragab MS, Awad M.
    J Med Chem; 1976 Nov 11; 19(11):1333-6. PubMed ID: 1003412
    [No Abstract] [Full Text] [Related]

  • 25. Comparative evaluation of acute toxicity and antitumor activity of IF-XXV preparation and holoxan.
    Kuśnierczyk H, Matuszyk J, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1989 Nov 11; 37(5-6):547-56. PubMed ID: 2487366
    [Abstract] [Full Text] [Related]

  • 26. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
    Voelcker G.
    Anticancer Drugs; 2018 Jan 11; 29(1):75-79. PubMed ID: 29219879
    [Abstract] [Full Text] [Related]

  • 27. Does acrolein contribute to the cytotoxicity of cyclophosphamide?
    Wrabetz E, Peter G, Hohorst HJ.
    J Cancer Res Clin Oncol; 1980 Jan 11; 98(2):119-26. PubMed ID: 7217177
    [Abstract] [Full Text] [Related]

  • 28. Synthesis, activation, and cytotoxicity of aldophosphamide analogues.
    Borch RF, Valente RR.
    J Med Chem; 1991 Oct 11; 34(10):3052-8. PubMed ID: 1920356
    [Abstract] [Full Text] [Related]

  • 29. Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.
    Takamizawa A, Matsumoto S, Iwata T, Tochino Y, Katagiri K.
    J Med Chem; 1974 Nov 11; 17(11):1237-9. PubMed ID: 4416021
    [No Abstract] [Full Text] [Related]

  • 30. Cytogenetic and antineoplastic effects of modified steroidal alkylators.
    Karapidaki I, Papageorgiou A, Geromichalos G, Fousteris M, Papaconstadinou I, Pairas G, Koutsourea A, Mourelatos D, Nikolaropoulos S, Lialiaris T.
    Genet Test Mol Biomarkers; 2010 Feb 11; 14(1):93-7. PubMed ID: 20025537
    [Abstract] [Full Text] [Related]

  • 31. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP, Trader MW, Frei E, Peters WP, Wolpert MK, Laster WR.
    Cancer Res; 1987 May 01; 47(9):2323-7. PubMed ID: 3567926
    [Abstract] [Full Text] [Related]

  • 32. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
    Schabel FM, Trader MW, Laster WR, Shaddix SC, Brockman RW.
    Cancer Treat Rep; 1976 Sep 01; 60(9):1325-33. PubMed ID: 1016968
    [Abstract] [Full Text] [Related]

  • 33. DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258).
    Gravatt GL, Baguley BC, Wilson WR, Denny WA.
    J Med Chem; 1994 Dec 09; 37(25):4338-45. PubMed ID: 7527862
    [Abstract] [Full Text] [Related]

  • 34. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.
    Ludeman SM, Boyd VL, Regan JB, Gallo KA, Zon G, Ishii K.
    J Med Chem; 1986 May 09; 29(5):716-27. PubMed ID: 3701785
    [Abstract] [Full Text] [Related]

  • 35. Structure-activity studies on organoselenium alkylating agents.
    Kang SI, Spears CP.
    J Pharm Sci; 1990 Jan 09; 79(1):57-62. PubMed ID: 2313578
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Isoquinolines. 6. Potential central nervous system antitumor agents. Nitrogen mustards of 3-amino-4-(p-aminophenyl)isoquinoline.
    Filer CN, Granchelli FE, Soloway AH, Neumeyer JL.
    J Med Chem; 1977 Nov 09; 20(11):1504-8. PubMed ID: 915914
    [Abstract] [Full Text] [Related]

  • 39. [Interaction of the three alkylating drugs, cyclophosphamide, ifosfamide and trofosfamide, with DNA and DNA-constituents in vitro (author's transl)].
    Lindemann H, Harbers E.
    Arzneimittelforschung; 1980 Nov 09; 30(12):2075-80. PubMed ID: 7194064
    [Abstract] [Full Text] [Related]

  • 40. Synthesis and structure-activity relationships of pre-activated analogs of cyclophosphamide (NSC-26271).
    Montgomery JA, Struck RF.
    Cancer Treat Rep; 1976 Apr 09; 60(4):381-93. PubMed ID: 945126
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.